Quarterly venture investment activity into neurology focused biopharma companies is back to pre-2020 level. This is no surprise given the investment slowdowns across all therapy area and broader life sciences. The drop seems to have stabilized however, and emerging...
August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors
Highlighted Deal Financial Comps
Total Deal Value:
Cost & Profit Split:
- RemeGen granted Seagen exclusive, worldwide rights, excluding parts of Asia, to co-develop and commercialize HER2-targeted ADC, disitamab vedotin for the treatment of several solid tumor types including urothelial, gastric, and breast cancer.
- RemeGen will retain development and commercialization rights in Asia excluding Japan and Singapore and will be responsible for all submissions specific to its territory.
- Seagen will lead global clinical development and RemeGen will fund and operate clinical trials attributable to its territory.
- RemeGen will receive $200M up front and is eligible for up to $2.4B in development, regulatory, and commercialization milestones, plus undisclosed tiered, high single-digit to mid-teens royalties.
Congrats to RemGen and Seagen for landing the DealForma August 2021 Top Biopharma Deal of the Month. The Deal of the Month for July 2021 was Arvinas and Pfizer’s PROTAC deal with $1B up front for ARV-471. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
We are tracking the biopharma R&D partnerships in neurology through the first half of 2023. Some notable licensing deals include Voyager's partnership with Neurocrine, which secured an upfront payment of $175 million and the potential to achieve up to $4.2 billion...